培米替尼进入医保了吗？

The U.S. Food and Drug Administration (FDA) has approved Incyte's drug for the treatment of adult patients with previously treated advanced cholangiocarcinoma; this is the world's first targeted therapy for cholangiocarcinoma.

Cholangiocarcinoma is a rare cancer that develops in the long, thin bile ducts that carry digestive juices from the liver to the gallbladder and small intestine. At the time of diagnosis, most patients with cholangiocarcinoma have an advanced stage, meaning they cannot undergo surgical treatment. For these patients, chemotherapy combinations have become the standard initial treatment. Fibrocyte growth factor receptor 2 (FGFR2) fusions are found in the tumors of approximately 9% to 14% of patients with cholangiocarcinoma. Pemetinib is approved for patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or other rearrangements. Pemetinib tablets prevent the growth and spread of tumors by inhibiting FGFR2 in tumor cells.

Pemetinib is a selective fibroblast growth factor receptor (FGFR) inhibitor that inhibits FGFR1, FGFR2, and FGFR3. FGFRs play an important role in tumor cell proliferation, survival, migration, and neovascularization. The fusion, rearrangement, translocation and amplification of FGFRs genes are closely related to the occurrence and progression of various cancers. The FDA has granted pemetinib Breakthrough Therapy Designation for the treatment of patients with previously treated advanced/metastatic or unresectable cholangiocarcinoma harboring FGFR2 gene translocations, as well as Orphan Drug Designation for the treatment of cholangiocarcinoma.

Has pemetinib been included in medical insurance?

It is reported that it has not been officially launched in China yet, so there is no medical insurance to speak of!

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: